GH1 and hydrops fetalis: Furthermore, although of included studies were not event-driven, the pooled analysis revealed significantly lower risk of worsening HF (by 48%), as well as a reduced risk for a composite outcome (death, worsening HF, or VT) (by 41%) in patients receiving GH compared to placebo.